CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 148 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $84,510 | +43.8% | 5,668 | +5.6% | 0.00% | +33.3% |
| Q2 2023 | $58,780 | +208.2% | 5,368 | -12.5% | 0.00% | +200.0% |
| Q1 2022 | $19,071 | -73.9% | 6,132 | -69.4% | 0.00% | 0.0% |
| Q3 2021 | $73,150 | -28.1% | 20,041 | -10.5% | 0.00% | -50.0% |
| Q1 2021 | $101,710 | +66.9% | 22,403 | +111.1% | 0.00% | +100.0% |
| Q4 2020 | $60,924 | -43.4% | 10,614 | -28.6% | 0.00% | -50.0% |
| Q3 2020 | $107,666 | +28.2% | 14,871 | -38.2% | 0.00% | +100.0% |
| Q2 2020 | $84,015 | -20.3% | 24,073 | +16.9% | 0.00% | -50.0% |
| Q3 2019 | $105,467 | -26.0% | 20,599 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $142,484 | -46.1% | 19,900 | 0.0% | 0.00% | -60.0% |
| Q1 2019 | $264,272 | +68.7% | 19,900 | 0.0% | 0.01% | +66.7% |
| Q4 2018 | $156,613 | -29.0% | 19,900 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $220,492 | -99.9% | 19,900 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $267,058,000 | – | 19,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 1,653,495 | $10,367,414 | 8.97% |
| Versant Venture Management, LLC | 543,753 | $3,409,330 | 7.06% |
| TCG Crossover Management, LLC | 5,905,400 | $37,026,858 | 6.54% |
| COMMODORE CAPITAL LP | 5,738,500 | $35,980 | 5.42% |
| Foresite Capital Management IV, LLC | 1,787,094 | $11,205,079 | 4.79% |
| Saturn V Capital Management LP | 1,611,778 | $5,718,432 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 1,015,000 | $6,364,050 | 3.92% |
| Altium Capital Management LP | 1,025,000 | $6,426,750 | 3.27% |
| Affinity Asset Advisors, LLC | 1,143,531 | $7,169,939 | 2.81% |
| GREAT POINT PARTNERS LLC | 1,550,000 | $9,718,500 | 1.90% |